Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Non-cash Items (2016 - 2025)

Aptevo Therapeutics (APVO) has disclosed Non-cash Items for 10 consecutive years, with $40000.0 as the latest value for Q2 2025.

  • Quarterly Non-cash Items rose 455.25% to $40000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $40000.0 through Jun 2025, up 455.25% year-over-year, with the annual reading at $267.0 for FY2024, 99.89% down from the prior year.
  • Non-cash Items hit $40000.0 in Q2 2025 for Aptevo Therapeutics, roughly flat from $40000.0 in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $43.2 million in Q4 2021 to a low of $267.0 in Q4 2024.
  • Historically, Non-cash Items has averaged $3.2 million across 5 years, with a median of $193919.0 in 2022.
  • Biggest five-year swings in Non-cash Items: surged 2302.77% in 2021 and later crashed 99.89% in 2024.
  • Year by year, Non-cash Items stood at $43.2 million in 2021, then plummeted by 99.57% to $187838.0 in 2022, then skyrocketed by 32.21% to $248346.0 in 2023, then plummeted by 99.89% to $267.0 in 2024, then soared by 14881.27% to $40000.0 in 2025.
  • Business Quant data shows Non-cash Items for APVO at $40000.0 in Q2 2025, $40000.0 in Q1 2025, and $267.0 in Q4 2024.